Hutchison China MediTech upgraded to Buy with $18.50 price target

2026年9月3日18:16 (19d ago)

Daiwa upgraded Hutchison China MediTech Limited to Buy after its GSK licensing deal.
Daiwa set a new price target of $18.50 for HCM.
GSK received exclusive commercialization rights to HCM’s experimental cancer therapy.

Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa, which set a new price target of $18.50 after a major licensing deal with GSK. The agreement gives GSK exclusive rights to commercialize HCM’s experimental cancer therapy.